journal
MENU ▼
Read by QxMD icon Read
search

Expert Review of Pharmacoeconomics & Outcomes Research

journal
https://www.readbyqxmd.com/read/29303374/most-important-barriers-and-facilitators-of-hta-usage-in-decision-making-in-europe
#1
K L Cheung, S M A A Evers, H De Vries, P Levy, S Pokhrel, T Jones, M Danner, J Wentlandt, L Knufinke, S Mayer, M Hiligsmann
BACKGROUND: To enhance usage of health technology assessment (HTA) in decision-making, it is important to prioritise important barriers and facilitators to the uptake of HTA. This study aims to quantify and compare the relative importance of barriers and facilitators regarding the use of HTA in several European countries. METHODS: A survey containing two best-worst scaling (BWS) object case studies (i.e. barriers and facilitators) were conducted among 136 policy makers and HTA researchers from the Netherlands, Germany, France, and United Kingdom...
January 5, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29210308/using-multi-criteria-decision-analysis-to-appraise-orphan-drugs-a-systematic-review
#2
Carlotta Friedmann, Pierre Levy, Paul Hensel, Mickaël Hiligsmann
Multi-criteria decision analysis (MCDA) could potentially solve current methodological difficulties in the appraisal of orphan drugs. Areas covered: We provide an overview of the existing evidence regarding the use of MCDA in the appraisal of orphan drugs worldwide. Three databases (Pubmed, Embase, Web of Science) were searched for English, French and German literature published between January 2000 and April 2017. Full-text articles were supplemented with conference abstracts. A total of seven articles and six abstracts were identified...
December 20, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29243501/critical-analysis-of-valuation-and-strategical-orientation-of-merger-and-acquisition-deals-in-the-pharmaceutical-industry
#3
Raphaela Marie Louisa Dierks, Olivier Bruyère, Jean-Yves Reginster
the pharmaceutical industry is undergoing major shifts due to changing macro and micro factors. As the industry is highly capital intensive and patents are expiring, the outlook is on generating inorganic growth, mainly through M&A. Using the income valuation approach, one analyses two completed deals in 2016 above 1bn USD. Thereafter one outlines the main motives behind M&A deals and concluded by discussing whether M&A harms medical innovations. Areas covered: the paper is based on empirical study questioning existing literature in order to critically analyse valuation and the strategical orientation of pharmaceutical companies Expert commentary: pharmaceutical companies understand the changing market conditions and favour their expertise...
December 15, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29235882/early-warning-systems-for-the-management-of-chronic-heart-failure-a-systematic-literature-review-of-cost-effectiveness-models
#4
Fernando Albuquerque de Almeida, Maiwenn Al, Ron Koymans, Kadir Caliskan, Ankie Kerstens, Johan L Severens
Introduction Describing the general and methodological characteristics of decision-analytical models used in the economic evaluation of early warning systems for the management of chronic heart failure patients and performing a quality assessment of their methodological characteristics is expected to provide concise and useful insight to inform the future development of decision-analytical models in the field of heart failure management. Areas covered The literature on decision-analytical models for the economic evaluation of early warning systems for the management of chronic heart failure patients was systematically reviewed...
December 13, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29212394/management-of-dental-caries-among-children-a-look-at-the-cost-effectiveness
#5
Nathalia Miranda Ladewig, Lucila Basto Camargo, Tamara Kerber Tedesco, Isabela Floriano, Thais Gimenez, José Carlos P Imparato, Fausto Medeiros Mendes, Mariana Minatel Braga, Daniela Prócida Raggio
Dental caries is the most prevalent non-communicative disease worldwide. Although the etiological factors are well known for years, reducing the number of decayed and missing teeth in children still remains as a barrier. Preventive and curative options are numerous but little is known about their economical advantages. Selecting the intervention that offers the best balance of effectiveness and financial resources becomes crucial in the current situation of budget restrictions worldwide. Areas covered: This expert review summarizes available evidence on cost-effectiveness analyses of preventive and curative measures to manage dental caries in children...
December 7, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29187008/cost-effectiveness-analysis-of-the-use-of-high-flow-oxygen-through-nasal-cannula-in-intensive-care-units-in-nhs-england
#6
Emily Eaton Turner, Michelle Jenks
OBJECTIVE: To estimate the cost-effectiveness of Nasal High Flow (NHF) in the intensive care unit (ICU) compared with standard oxygen or non-invasive ventilation (NIV) from a UK NHS perspective. METHODS: Three cost-effectiveness models were developed to reflect scenarios of NHF use: first-line therapy (pre-intubation model); post-extubation in low-risk, and high-risk patients. All models used randomized control trial data on the incidence of intubation/re-intubation, events leading to intubation/re-intubation, mortality and complications...
December 5, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29192530/cost-effectiveness-analysis-of-infliximab-adalimumab-golimumab-and-vedolizumab-for-moderate-to-severe-ulcerative-colitis-in-spain
#7
Cristina Trigo-Vicente, Vicente Gimeno-Ballester, Raquel Montoiro-Allué, Alejandro López-Del Val
OBJECTIVES: Assess the efficiency of biologic treatment for moderate to severe ulcerative colitis (UC) which are indicated and financed for this pathology by Spain. METHODS: A Markov model was constructed to simulate the progression in a cohort of patients with moderate to severe UC. The perspective chosen was National Health Service with an over 10 years of time horizon, with a discount rate of 3%, and established threshold of €30,000/quality-adjusted life-year (QALY)...
December 2, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29188745/bariatric-surgery-versus-conservative-management-for-morbidly-obese-patients-in-spain-a-cost-effectiveness-analysis
#8
Raquel Sanchez-Santos, Esther Mariño Padin, Daniel Adam, Oleg Borisenko, Sergio Estevez Fernandez, Ester Carrera Dacosta, Sonia González Fernández, Juan Turnes Vazquez, Juan Carlos Ruiz de Adana, Felipe de la Cruz Vigo
BACKGROUND: We assessed the cost-effectiveness of bariatric surgery (BS) versus conservative management (CM) for treating morbid obesity in Spain. METHODS: We developed a probabilistic Markov model to estimate health outcomes, quality-adjusted life years (QALY), life years gained (LYG), and costs over lifetime and 10-year horizons. Combined common BS procedures were compared with CM. Clinical and utility inputs were obtained from the literature and resource use and costs from local sources (€2017)...
November 30, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29186996/an-assessment-of-innovative-pricing-schemes-for-the-communication-of-value-is-price-discrimination-and-two-part-pricing-a-way-forward
#9
Peter Hertzman, Paul Miller, Keith Tolley
With the introduction of new expensive medicines, traditional pricing schemes based on constructs such as price per pill/vial have been challenged. Potential innovative schemes could be either financial-based or performance-based. Within financial-based schemes the use of price discrimination is an emerging option, which we explore in this assessment. Areas covered: In the short term the price per indication approach is likely to become more prevalent for high cost, high benefit new pharmaceuticals, such as those emerging in oncology (e...
November 30, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29186995/toward-minimally-disruptive-management-of-symptomatic-endometriosis-reducing-low-value-care-and-the-burden-of-treatment
#10
Paolo Vercellini, Maria Pina Frattaruolo, Laura Buggio
No abstract text is available yet for this article.
November 30, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29183175/economic-evaluation-of-medical-tests-at-the-early-phases-of-development-a-systematic-review-of-empirical-studies
#11
Samuel N Frempong, Andrew J Sutton, Clare Davenport, Pelham Barton
There is little specific guidance on the implementation of cost-effectiveness modelling at the early stage of test development. The aim of this study was to review the literature in this field to examine the methodologies and tools that have been employed to date. Areas Covered: A systematic review to identify relevant studies in established literature databases. Five studies were identified and included for narrative synthesis. These studies revealed that there is no consistent approach in this growing field...
November 29, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29145746/clinical-efficacy-and-economic-evaluation-of-online-cognitive-behavioral-therapy-for-major-depressive-disorder-a-systematic-review-and-meta-analysis
#12
Elayne Ahern, Stephen Kinsella, Maria Semkovska
Leading cause of disability worldwide, depression is the most prevalent mental disorder with growing societal costs. As mental health services demand often outweighs provision, accessible treatment options are needed. Our systematic review and meta-analysis evaluated the clinical efficacy and economic evidence for the use of online cognitive behavioral therapy (oCBT), as an accessible treatment solution for depression. Areas covered: Electronic databases were searched for controlled trials published between 2006 and 2016...
November 17, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29039214/pharmaceutical-pricing-in-japan-market-evidence-for-rheumatoid-arthritis-treatment
#13
Jörg Mahlich, Isao Kamae, Rosarin Sruamsiri
BACKGROUND: Drug price setting is one of the key challenges faced by the Japanese health care system. This study aims to identify the determinants of drug price in Japan using the example of the rheumatoid arthritis (RA) treatment market. RESEARCH DESIGN AND METHODS: In order to compare prices across different products, we calculated prices per defined daily dose using WHO methodology. Price determinants were calculated both at launch and over time using IMS quarterly data on medicines approved for RA treatment in Japan from 2012 to 2015...
November 3, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29148854/comparative-effectiveness-of-lipid-lowering-treatments-to-reduce-cardiovascular-disease
#14
REVIEW
Dong-Churl Suh, Scott K Griggs, Emmett R Henderson, Seung-Mi Lee, Taehwan Park
The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor is a new treatment option for patients with hypercholesterolemia. The objective of this study was to systematically review the cost-effectiveness of lipid-lowering agents. Areas covered: Based on Pubmed, Embase, and Cochrane Database of Systematic Reviews, we identified 29 relevant articles. Studies found statins were cost-effective compared with placebo or no treatment in general. Atorvastatin was reported to be cost-effective against simvastatin...
February 2018: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29058478/improving-the-quality-of-discrete-choice-experiments-in-health-how-can-we-assess-validity-and-reliability
#15
REVIEW
Ellen M Janssen, Deborah A Marshall, A Brett Hauber, John F P Bridges
The recent endorsement of discrete-choice experiments (DCEs) and other stated-preference methods by regulatory and health technology assessment (HTA) agencies has placed a greater focus on demonstrating the validity and reliability of preference results. Areas covered: We present a practical overview of tests of validity and reliability that have been applied in the health DCE literature and explore other study qualities of DCEs. From the published literature, we identify a variety of methods to assess the validity and reliability of DCEs...
December 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/28949250/the-challenges-of-implementing-pharmacogenomic-testing-in-the-clinic
#16
REVIEW
Ann M Moyer, Pedro J Caraballo
Pharmacogenomic testing has the potential to greatly benefit patients by enabling personalization of medication management, ensuring better efficacy and decreasing the risk of side effects. However, to fully realize the potential of pharmacogenomic testing, there are several important issues that must be addressed. Areas covered: In this expert review we discuss current challenges impacting the implementation of pharmacogenomic testing in the clinical practice. We emphasize issues related to testing methods, reporting of the results, test selection, clinical interpretation of the results, cost-effectiveness, and the long-term use of pharmacogenomic results in clinical practice...
December 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/28649881/cost-effectiveness-analysis-of-insulin-degludec-compared-with-insulin-glargine-u100-for-the-management-of-type-1-and-type-2-diabetes-mellitus-from-the-spanish-national-health-system-perspective
#17
Pedro Mezquita-Raya, Josep Darbà, Meritxell Ascanio, Antonio Ramírez de Arellano
BACKGROUND: The objective of this study was to assess the cost-effectiveness of insulin degludec versus insulin glargine, from the Spanish NHS in three groups of patients. METHODS: A short-term cost utility model was developed to estimate effectiveness results in terms of the total number of hypoglycaemic events and their disutility impact throughout the year on the initial level of quality of life for patients in each treatment. RESULTS: Degludec was the dominant strategy for T2DM BOT and exhibited an incremental cost-effectiveness ratio of 52...
December 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/28504026/the-influence-of-time-horizon-on-results-of-cost-effectiveness-analyses
#18
David D Kim, Colby L Wilkinson, Elle F Pope, James D Chambers, Joshua T Cohen, Peter J Neumann
BACKGROUND: Debates persist on the appropriate time horizon from a payer's perspective and how the time horizon in cost-effectiveness analysis (CEA) influences the value assessment. METHODS: We systematically reviewed the Tufts Medical Center CEA Registry and identified US-based studies that used a payer perspective from 2005-2014. We classified the identified CEAs as short-term (time horizon ≤ 5 years) and long-term (> 5 years), and examined associations between study characteristics and the specified time horizon...
December 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/28503962/impact-of-price-deregulation-policy-on-the-affordability-of-essential-medicines-for-women-s-health-a-panel-data-analysis
#19
Junjie Liu, Liming Wang, Chenxi Liu, Xinping Zhang
BACKGROUND: A new policy which required deregulation on prices of off-patent medicines for women's health during procurement was introduced in China in September 2015. The current study examines this policy's impact on the affordability of essential medicines for women's health. METHODS: Based on product-level panel data, a fixed effect regression model is employed by using procurement records from Hubei Centralist Tender for Drug Purchase platform. In the model, Affordability was measured with prices...
December 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/28434387/cost-utility-of-biological-treatment-sequences-for-luminal-crohn-s-disease-in-europe
#20
Fanni Rencz, László Gulácsi, Márta Péntek, Krisztina B Gecse, Axel Dignass, Jonas Halfvarson, Fernando Gomollón, Petra Baji, Laurent Peyrin-Biroulet, Peter L Lakatos, Valentin Brodszky
BACKGROUND: This study aims to compare the cost-effectiveness of treatment sequences with available biologics, including adalimumab (ADA), biosimilar infliximab (bsIFX), originator infliximab (IFX) and vedolizumab (VEDO) for luminal Crohn's disease in nine European countries. METHODS: A Markov-model was constructed to simulate five-year medical costs and quality-adjusted life years (QALYs). Data on clinical efficacy were obtained from randomised controlled trials...
December 2017: Expert Review of Pharmacoeconomics & Outcomes Research
journal
journal
39911
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"